Biotech Values

[DewDiligence]

VRTX—Even before they knew how successful they would be in CF, management was already guiding investors to stop thinking of VRTX as an HCV company. From #msg-76347002 (Jun 2012):

…VRTX’s CEO said on today’s GS webcast that there will flat-out be no new HCV acquisitions. When pressed about what he would do if the Alios nukes failed to make the grade, Leiden said VRTX would maximize Incivek’s sales through 2014 and would simply “sit out the second wave” of HCV treatment (i.e. the all-oral phase).